Telling yourself you're doing the best with what you have is one of many examples of compassionate self-care, writes ...

The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Heidi Crayton, MD, and Maria Lopes, MD, discuss the impact of multiple sclerosis on patients, families, and caregivers, differentiate relapsing forms (relapsing-remitting and primary progressive) from ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

Disease-Modifying Therapy Comparison and Side Effects ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

The pain experience in women with RRMS has significant practice implications for nursing. The findings from this study may assist nurses practicing in hospitals and other settings within the community ...

Mavenclad (cladribine) is a medicine used to treat relapsing forms of multiple sclerosis (MS) including relapsing-remitting MS and active secondary progressive MS. Relapsing forms of MS have temporary ...

CombiRx is a randomized clinical trial to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...